Intravenous Equipment

Intravenous Equipment

Global Intravenous Equipment Market to Reach US$14.2 Billion by 2030

The global market for Intravenous Equipment estimated at US$11.2 Billion in the year 2023, is expected to reach US$14.2 Billion by 2030, growing at a CAGR of 3.5% over the analysis period 2023-2030. IV Catheters, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Securement Devices segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.0 Billion While China is Forecast to Grow at 6.2% CAGR

The Intravenous Equipment market in the U.S. is estimated at US$3.0 Billion in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.9 Billion by the year 2030 trailing a CAGR of 6.2% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 4.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global Intravenous Equipment Market - Key Trends and Drivers Summarized

Intravenous (IV) equipment is essential for administering fluids and medications directly into the bloodstream. This equipment typically includes tubing that connects a fluid-filled bag to a patient`s vein, usually located in the hand or arm. The flow of fluids and medicines is commonly facilitated by gravity, which allows the contents of the bag to be delivered steadily and reliably into the bloodstream. This method is critical for treatments that require rapid and efficient delivery of therapeutic substances. The infusion therapy market is expanding rapidly due to the growing prevalence of chronic illnesses such as cancer and diabetes, along with an aging population requiring continuous treatment. Market leaders such as Baxter, Fresenius, B. Braun, and Terumo dominate the sector, but smaller competitors are making strides with innovative technology and delivery systems.

One of the most significant trends propelling market growth is the transition of infusion therapy to alternative care settings such as specialty clinics, ambulatory surgery centers (ASCs), and home care. Specialty clinics offer personalized, condition-specific treatment with shorter wait times and flexible scheduling. ASCs provide complex care without the higher costs of hospitals, while home care enables patients to receive treatment in a familiar, comfortable setting. Portable and wearable infusion pumps are a major technological development, offering precise medication delivery with patient mobility. Meanwhile, antimicrobial-coated IV sets, needleless connectors, and stopcocks ensure improved safety and efficiency.  Several trends are shaping the IV filter market and contributing to its growth. One of the most important is the development of specialized membranes in IV filters, including 0.2-μm pore membranes for bacteria and 1.2-μm mesh membranes for lipids. These tailored membranes enable precise removal of particles such as bacteria, air bubbles, and lipid clusters from intravenous solutions.

Despite promising market potential, challenges such as a shortage of trained healthcare professionals and high equipment development costs remain. In rural areas, limited access to trained professionals exacerbates this shortage. High R&D and production costs also lead to increased prices, restricting access for some patients and straining healthcare budgets. Close collaboration between medical device companies, healthcare providers, and insurers is essential to create innovative and affordable equipment. Overall, the infusion therapy market has a bright future, with significant potential to enhance patient outcomes and quality of life through continuous advancements.

Select Competitors (Total 91 Featured) -

• AngioDynamics Inc.
• Arcomed AG
• ASCOR S.A.
• B. Braun Melsungen AG
• Baxter International Inc.
• Becton, Dickinson and Company
• F. Hoffmann-La Roche Ltd.
• Fresenius SE & Co. KGaA
• Halyard Health Inc.
• ICU Medical Inc.
• Insulet Corp.
• Medtronic PLC
• Moog Inc.
• Nipro Corporation
• Smiths Medical
• Tandem Diabetes Care Inc.
• Teleflex Inc.
• Terumo Corp.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.